Figure 1. Competition assay demonstrating Anti-SIRPα DM8 can block CD47 binding to THP-1 cells. IC50=30.88ng/ml.
Anti-SIRPα(DM8)流式结合滴度检测实验
Figure 2.Flow cytometry data of serially titrated Anti-SIRPα (Clone: DM8). The Y-axis represents the mean fluorescence intensity (MFI) while the X-axis represents the concentration of IgG used.
未来,我们希望和对该靶点感兴趣的机构一起合作,继续深入开发以SIRPα为靶点的功能性抗体产品。目前Anti-SIRPα(DM8)克隆已上线,欢迎垂询和测试。
参考文献:
[1]Chao, Mark P., Irving L. Weissman, and Ravindra Majeti. "The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications." Current opinion in immunology 24.2 (2012): 225-232.
[2]Ring, Nan Guo, et al. "Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity." Proceedings of the National Academy of Sciences 114.49 (2017): E10578-E10585.
[3]Liu, Jie, et al. "Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy." JCI insight 5.12 (2020).